Contact us for free information or to start a free case review.
Multaq® has only one prescribed dosage. One 400 mg tablet should be taken in the morning and one in the evening. Both should be taken with a meal.
The tablets are white and film coated; they should be taken orally. They are oblong-shaped and engraved on one side with a double wave marking and on the other side with the code "4142".
The heart medication is given to reduce the risk of needing hospitalization in patients with atrial fibrillation (irregular heartbeat, sometimes rapid), atrial flutter (rapid heartbeat), who also have high blood pressure, history of stroke, certain other heart problems, or who will be cardioverted (shock to the heart to reset it to a normal rhythm).
Multaq® should not be given to patients with serious heart failure or moderate heart failure that has deteriorated and required the patient to be hospitalized or referred to a specialized heart failure clinic. Other patients who should not be given the drug are those with heart problems known as second- or third-degree atrioventricular block or sick sinus syndrome (except when the patient has a functioning pacemaker). Other patients who should not take Multaq® are those with bradycardia (a slow heart rate, usually defined as slower than 50 or 60 beats per minute).
It is possible to take too much Multaq®.
An overdose may lead to:
If an overdose occurs, according to the drug label information, the patient's heart rhythm and blood pressure should be monitored closely. The label says "treatment should be supportive and based on symptoms." There is no information on whether Multaq® can be removed from the body by dialysis and no specific antidote is available. If the overdose was recent, pumping the stomach may be helpful.
Multaq® has been linked to 387 reports of adverse effects, including 24 cases of death. Over dosage may also lead to serious side effects. If you think you've suffered harm as a result of taking the drug, contact our Multaq® lawyers for help. We may be able to get you compensation for your injuries.
The FDA notified healthcare professionals about new findings that link Multaq® to severe liver injuries, Jan. 14, 2011. The agency said there were two report...
Copyright © 2001 - 2012 Online Lawyer Source | Legal Marketing Site Designed by eJustice
ATTORNEY ADVERTISEMENT—Thank you for your visit. The content published on this website was not written by medical professionals and should not, at any point, be mistaken for medical advice. Furthermore, the information on this site is intended for educational purposes only and should never interfere with a patient/site visitor and his or her healthcare provider. In addition, viewing the content on this website, requesting additional information, or transmitting information through a contact form should never be considered the formation of an attorney-client relationship. The material published on this site is general and may not apply to your specific circumstances. Every case comes with its own set of unique circumstances; past success discussed on this site does not guarantee future performance. Information found on this website should not be used as incentive to act without seeking counsel from a professional. For more information, please read our disclaimer.